Staphylococcus aureus can cause a variety of diseases in humans and animals, including skin abscesses, pneumonia, endocarditis, and osteomyelitis (
1). It widely exists in the environment and the skin and mucosal surfaces of humans and animals; however, it is documented that its elimination is challenging. Moreover, multi-drug-resistant strains usually lead to a high mortality rate and pose serious health threats to humans and animals (
2). Antibiotic therapy is an effective prevention and control method for the
S. aureus infection. However, in recent years, due to the horizontal gene transfer of genes resistant to antibiotics by mobile genetic elements (MGE), including staphylococcal cassette chromosomes (SCC), transposons,
S. aureus pathogenicity islands, plasmids, and bacteriophages, the degree and the rate of drug resistance of the
S. aureus have experienced a sharp increase (
3). Furthermore, the emergence of vancomycin-resistant
S. aureus (VRSA) and Methicillin-resistant
S. aureus (MRSA) has greatly increased the difficulty of
S. aureus infection prevention and control (
4,
5); hence, developing new antibiotics or finding effective alternative therapies is recommended. Bacteriophages with acceptable therapeutic effects and lytic enzymes have attracted the attention of many researchers and have tremendous therapeutic potential (
6).
Bacteriophage (Phage), widely found in nature, is a kind of virus that infects bacteria, is reproduced inside them, and plays a role in bacteriolysis (
7). Phage therapy is widely being used in different fields of medical research. It is considered an effective alternative treatment for local infections such as otitis, infected burns, and bone and osteoarticular infections (
8). For the first time, Sybesma et al. demonstrated the lytic activity of phage cocktails against
Escherichia coli and
Klebsiella pneumoniae in the case of transurethral resection of the prostate combined with phage therapy (
9).
In animal models, Dufour et al. demonstrated the ability of phages to treat
E. coli-mediated urinary tract infections. The same dose of phage treatment significantly decreased bacterial load in a renal
E. coli infection and
E. coli pneumonia model (
6,
10,
11). Moreover, due to the strong specificity of phages, which mainly mediate adsorption and infection by receptors on the bacterium's membrane, phages have no significant effect on human and animal cells. They are not prone to have side effects (
12). However, the constant emergence of resistant
S. aureus to current antibiotics and the increased prevalence of MRSA are significant setbacks for treating infections, especially urinary tract infections induced by this pathogen (
13). Accordingly, the increasing dilemma posed by antimicrobial resistance has aroused a global interest in bacteriophage therapy, making it a promising therapeutic approach to drug-resistant bacteria infections (
14).